{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T13:12:53Z","timestamp":1719234773944},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Partly supported by an unrestricted research grant from AbbVie","award":["-"],"award-info":[{"award-number":["-"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Axial spondyloarthritis (axSpA) frequently presents during working age and therefore impacts work participation. Biologic therapies have demonstrated a positive impact on work-related outcomes in clinical trials but real world data are limited. Therefore, we investigated the prevalence and predictors of work impairment and disability among axSpA patients attending a biologic therapy clinic.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a single-centre, cross-sectional study of patients with axSpA treated with biologic therapy. Work participation was assessed with the Work Productivity and Activity Impairment (WPAI) Questionnaire. Work outcomes (presenteeism, absenteeism, health-related job loss) were compared for gender, time since diagnosis, smoking status and disease outcome measures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data were available for 165 patients (mean age 47.6\u2009years, 75% male, 21% current smokers). Mean time since diagnosis was 15.5\u2009years and mean duration of biologic therapy 4.7\u2009years; 19\/165 (11.5%) were on a tapered-dose regimen. Occupational data were available for 144 patients amongst whom 101 (70.1%) were either currently employed or in full time education. Of those eligible to work, 17\/118 (14.4%) reported inability to work due to their axSpA. Amongst those in employment, 10.8% reported absenteeism due to axSpA in the week prior to their clinic visit (mean hours missed\u2009=\u200913). The mean work productivity impairment was 23%. Higher disease activity (BASDAI) and markers of global health, quality of life and pain, (BAS-G, ASQoL and spinal pain VAS) were associated with axSpA related job loss, absenteeism and presenteeism.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this group of axSpA patients on biologic therapy (mean age 47.6\u2009years), almost 1 in 6 (14.4%) reported axSpA related job loss. Poor work outcomes: axSpA-related work disability, absenteeism and presenteeism were associated with poorer scores for patient-reported disease outcome measures. Strategies for enhancing work productivity should be directed towards those patients at risk of poor work outcomes. More data are needed including details of the types of work that are most difficult with axSpA.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12891-020-03247-9","type":"journal-article","created":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T13:03:32Z","timestamp":1586178212000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Amongst patients taking biologic therapies for axial spondyloarthritis, which factors are associated with work non-participation?"],"prefix":"10.1186","volume":"21","author":[{"given":"Tom","family":"Nadin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinny","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Holroyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Walker-Bone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,6]]},"reference":[{"key":"3247_CR1","unstructured":"Black C. Working for a healthier tomorrow. In: Dame Carol Black\u2019s Review of the Health of Britain\u2019s Working Age Population; 2008. www.dwp.gov.uk\/docs\/hwwb-workingfor-a-healthier-tomorow.pdf. Accessed 1 May 2019."},{"issue":"11","key":"3247_CR2","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s10067-009-1249-1","volume":"28","author":"E Cakar","year":"2009","unstructured":"Cakar E, Taskaynatan MA, Dincer U, Kiralp MZ, Durmus O, Ozgul A. Work disability in ankylosing spondylitis: differences among working and work-disabled patients. Clin Rheumatol. 2009;28(11):1309\u201314.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"3247_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10067-010-1669-y","volume":"30","author":"C Ramos-Remus","year":"2011","unstructured":"Ramos-Remus C, Hernandez-Rios G, Duran-Barragan S, Sanchez-Ortiz A, Aceves-Avila FJ, Castillo-Ortiz JD, et al. Fifteen-year trends of long-term disability and sick leaves in ankylosing spondylitis. Clin Rheumatol. 2011;30(3):361\u20137.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"3247_CR4","doi-asserted-by":"crossref","first-page":"e000659","DOI":"10.1136\/rmdopen-2018-000659","volume":"4","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Braun J, Rudwaleit M, Purcaru O, Kavanaugh AF. Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study. RMD Open. 2018;4(1):e000659.","journal-title":"RMD Open"},{"issue":"6","key":"3247_CR5","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3899\/jrheum.131003","volume":"41","author":"D van der Heijde","year":"2014","unstructured":"van der Heijde D, Deodhar A, Braun J, Mack M, Hsu B, Gathany TA, et al. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial. J Rheumatol. 2014;41(6):1095\u2013103.","journal-title":"J Rheumatol"},{"issue":"1","key":"3247_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/rheumatology\/kev267","volume":"55","author":"D van der Heijde","year":"2016","unstructured":"van der Heijde D, Joshi A, Pangan AL, Chen N, Betts K, Mittal M, et al. ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis. Rheumatology (Oxford). 2016;55(1):80\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"3247_CR7","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/art.22097","volume":"55","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Han C, DeVlam K, Burmester G, van den Bosch F, Williamson P, et al. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Rheum. 2006;55(4):569\u201374.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"3247_CR8","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3899\/jrheum.141313","volume":"42","author":"M Dougados","year":"2015","unstructured":"Dougados M, Tsai WC, Saaibi DL, Bonin R, Bukowski J, Pedersen R, et al. Evaluation of health outcomes with Etanercept treatment in patients with early nonradiographic axial Spondyloarthritis. J Rheumatol. 2015;42(10):1835\u201341.","journal-title":"J Rheumatol"},{"issue":"12","key":"3247_CR9","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1002\/art.39805","volume":"68","author":"AA Deodhar","year":"2016","unstructured":"Deodhar AA, Dougados M, Baeten DL, Cheng-Chung Wei J, Geusens P, Readie A, et al. Effect of Secukinumab on patient-reported outcomes in patients with active Ankylosing spondylitis: a phase III randomized trial (MEASURE 1). Arthritis Rheum. 2016;68(12):2901\u201310.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"3247_CR10","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1136\/ard.2009.121327","volume":"69","author":"N Barkham","year":"2010","unstructured":"Barkham N, Coates LC, Keen H, Hensor E, Fraser A, Redmond A, et al. Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis. 2010;69(11):1926\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"3247_CR11","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1136\/annrheumdis-2018-213590","volume":"77","author":"J Shim","year":"2018","unstructured":"Shim J, Jones GT, Pathan EMI, Macfarlane GJ. Impact of biological therapy on work outcomes in patients with axial spondyloarthritis: results from the British Society for Rheumatology biologics register (BSRBR-AS) and meta-analysis. Ann Rheum Dis. 2018;77(11):1578\u201384.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3247_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13075-017-1333-x","volume":"19","author":"L van Hoeven","year":"2017","unstructured":"van Hoeven L, Boonen A, Hazes JMW, Weel A. Work outcome in yet undiagnosed patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis; results of a cross-sectional study among patients with chronic low back pain. Arthritis Res Ther. 2017;19(1):143.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3247_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13075-016-1162-3","volume":"18","author":"M de Hooge","year":"2016","unstructured":"de Hooge M, Ramonda R, Lorenzin M, Frallonardo P, Punzi L, Ortolan A, et al. Work productivity is associated with disease activity and functional ability in Italian patients with early axial spondyloarthritis: an observational study from the SPACE cohort. Arthritis Res Ther. 2016;18(1):265.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"3247_CR14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777\u201383. https:\/\/doi.org\/10.1136\/ard.2009.108233.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3247_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"3247_CR16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/rheumatology\/kep457","volume":"49","author":"MC Reilly","year":"2010","unstructured":"Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D. Validity, reliability and responsiveness of the work productivity and activity impairment questionnaire in ankylosing spondylitis. Rheumatology (Oxford). 2010;49(4):812\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"3247_CR17","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1136\/ard.2009.116764","volume":"69","author":"A Boonen","year":"2010","unstructured":"Boonen A, Brinkhuizen T, Landewe R, van der Heijde D, Severens JL. Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Ann Rheum Dis. 2010;69(6):1123\u20138.","journal-title":"Ann Rheum Dis"},{"key":"3247_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13075-016-0977-2","volume":"18","author":"R Ramonda","year":"2016","unstructured":"Ramonda R, Marchesoni A, Carletto A, Bianchi G, Cutolo M, Ferraccioli G, et al. Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey. Arthritis Res Ther. 2016;18:78.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"3247_CR19","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.3899\/jrheum.140396","volume":"41","author":"MA van der Weijden","year":"2014","unstructured":"van der Weijden MA, Boonen A, van der Horst-Bruinsma IE. Problems in work participation and resource use should not be underestimated in patients with early spondyloarthritis. J Rheumatol. 2014;41(12):2413\u201320.","journal-title":"J Rheumatol"},{"issue":"1","key":"3247_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13075-018-1598-8","volume":"20","author":"KL Druce","year":"2018","unstructured":"Druce KL, Aikman L, Dilleen M, Burden A, Szczypa P, Basu N. Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients. Arthritis Res Ther. 2018;20(1):96.","journal-title":"Arthritis Res Ther"},{"key":"3247_CR21","doi-asserted-by":"publisher","unstructured":"Macfarlane GJ, Shim J, Jones GT, Walker-Bone K, Pathan E, Dean LE. Identifying persons with axial Spondyloarthritis at risk of poor work outcome: results from the British Society for Rheumatology biologics register. J Rheumatol. 2018;46(2):145\u201352. https:\/\/doi.org\/10.3899\/jrheum.180477. Epub 2018 Nov 1.","DOI":"10.3899\/jrheum.180477"},{"issue":"1","key":"3247_CR22","doi-asserted-by":"publisher","first-page":"e000230","DOI":"10.1136\/rmdopen-2015-000230","volume":"2","author":"S Harvard","year":"2016","unstructured":"Harvard S, Guh D, Bansback N, Richette P, Dougados M, Anis A, et al. Costs of early spondyloarthritis: estimates from the first 3 years of the DESIR cohort. RMD Open. 2016;2(1):e000230.","journal-title":"RMD Open"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-020-03247-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12891-020-03247-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-020-03247-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T15:30:58Z","timestamp":1696001458000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-020-03247-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,6]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3247"],"URL":"https:\/\/doi.org\/10.1186\/s12891-020-03247-9","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,6]]},"assertion":[{"value":"3 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the West of Scotland Research Ethics Service. Written informed consent was obtained from the subjects.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent to publish findings from this study was obtained from the subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TN: None declared; DW: Grant\/research support from: Janssen, MSD, Pfizer, AbbVie, Novartis; CH: Consultant for AbbVie, Novartis, Napp and UCB. Speakers bureau: AbbVie, BMS, Chugai, Janssen, Lilly, Novartis, UCB.KW-B: None declared, CJE: Consultant for: AbbVie, Pfizer, Lilly, Celltrion, Mundipharma, Samsung, Anthera, UCB, Celgene, Roche, BMS, Jansen, Novartis and UCB., Speakers bureau: AbbVie, Pfizer, Lilly, Celltrion, Mundipharma, Samsung, Anthera, UCB, Celgene, Roche, BMS, Jansen, Novartis and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"209"}}